|
|
|
|
The incidence of persistent antibody positivity associated with natalizumab if 6%. Reduced clinical efficacy is apparent in persistently positive patients. Patients with a suboptimal clinical response or persistent infusion-related adverse events should be considered for antibody testing. |
|